ArticleClinical ophthalmology (Auckland, N.Z.)2025
Peripherex Home Visual Field Demonstrates High Test-Retest Reliability, Validity.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Assessment of disease and progression is one of the greatest unmet needs in glaucoma care. Moving visual field testing into the home stands to increase access and increase testing frequency to address these unmet needs. Here, we test a novel home-based app (Peripherex Visual Field Test or PRX-VFT) that leverages eye tracking in a short, "gamified" software environment, against in-office Humphrey Field Analyzer (HFA) data. Methods: Observational, multicenter, open-label clinical trial in patients diagnosed with glaucoma, glaucoma suspect, or ocular hypertension. Results: A total of 190 PRX tests were performed with 97 on the left eye and 93 on the right eye, derived from 36 eyes of 19 patients who also had reliable, matched HFA data. Patients were 58% female with a mean (SD) age of 61.5 (11.9) years (range 26-78). Test-retest reliability was good, with interclass correlation coefficient of 0.7596. Detection of abnormal fields was excellent, with a sensitivity of 95.7% and a negative predictive value (NPV) of 98.27%. Detection of normal fields was very good, with a specificity of 79.26% and a positive predictive value (PPV) of 66.36%. Patients reported that compared to HFA, PRX-VFT was easier and more fun to complete. Conclusion: In-home visual field testing using PRX-VFT on a patient's personal computer met its primary clinical trial endpoints, was feasible, and showed excellent statistical correlation to in-office HFA testing. PRX-VFT represents an opportunity for enhancing patient care at minimal additional equipment cost to the patient or healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.